RU97111163A - FACTION OF KERATAN SULPHATOLIGOSACCHARIDES AND ITS PHARMACEUTICAL PRODUCT - Google Patents
FACTION OF KERATAN SULPHATOLIGOSACCHARIDES AND ITS PHARMACEUTICAL PRODUCTInfo
- Publication number
- RU97111163A RU97111163A RU97111163/14A RU97111163A RU97111163A RU 97111163 A RU97111163 A RU 97111163A RU 97111163/14 A RU97111163/14 A RU 97111163/14A RU 97111163 A RU97111163 A RU 97111163A RU 97111163 A RU97111163 A RU 97111163A
- Authority
- RU
- Russia
- Prior art keywords
- keratan sulfate
- 4g1cnac
- oligosaccharide
- sulfated
- acetyl
- Prior art date
Links
- KXCLCNHUUKTANI-RBIYJLQWSA-N Keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 title claims 56
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229920000288 Keratan sulfate Polymers 0.000 claims 52
- 229920001542 oligosaccharide Polymers 0.000 claims 45
- 150000002482 oligosaccharides Polymers 0.000 claims 45
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 13
- 102000004190 Enzymes Human genes 0.000 claims 13
- 108090000790 Enzymes Proteins 0.000 claims 13
- 229960002442 Glucosamine Drugs 0.000 claims 13
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 13
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 claims 12
- 125000003047 N-acetyl group Chemical group 0.000 claims 10
- 239000000411 inducer Substances 0.000 claims 10
- 238000003776 cleavage reaction Methods 0.000 claims 9
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical group N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 claims 7
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 6
- 239000008351 acetate buffer Substances 0.000 claims 6
- 150000001720 carbohydrates Chemical group 0.000 claims 6
- 150000002016 disaccharides Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010059512 Apoptosis Diseases 0.000 claims 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 5
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims 5
- 229940060155 Neuac Drugs 0.000 claims 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims 5
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 5
- 239000000043 antiallergic agent Substances 0.000 claims 5
- 230000006907 apoptotic process Effects 0.000 claims 5
- 230000024245 cell differentiation Effects 0.000 claims 5
- 239000002955 immunomodulating agent Substances 0.000 claims 5
- 230000002584 immunomodulator Effects 0.000 claims 5
- 229940121354 immunomodulators Drugs 0.000 claims 5
- 239000004615 ingredient Substances 0.000 claims 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 5
- 238000006243 chemical reaction Methods 0.000 claims 4
- 239000000470 constituent Substances 0.000 claims 4
- -1 disulfated N-acetyl saccharide Chemical class 0.000 claims 4
- WKPUACLQLIIVJJ-RHKLHVFKSA-M (2S,3R,4R,5S,6R)-4-hydroxy-3-methoxy-6-[(2S,3R,4S,5S,6R)-6-methoxy-4-oxido-5-(sulfooxyamino)-2-(sulfooxymethyl)oxan-3-yl]oxy-5-sulfooxyoxane-2-carboxylate Chemical compound [O-][C@H]1[C@H](NOS(O)(=O)=O)[C@H](OC)O[C@@H](COS(O)(=O)=O)[C@@H]1O[C@H]1[C@@H](OS(O)(=O)=O)[C@H](O)[C@@H](OC)[C@@H](C([O-])=O)O1 WKPUACLQLIIVJJ-RHKLHVFKSA-M 0.000 claims 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L Dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 2
- 102000033147 ERVK-25 Human genes 0.000 claims 2
- 229920002971 Heparan sulfate Polymers 0.000 claims 2
- 108091005503 Nucleic proteins Proteins 0.000 claims 2
- 108091005771 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims 2
- 230000000593 degrading Effects 0.000 claims 2
- 229940051593 dermatan sulfate Drugs 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 238000005194 fractionation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 101710004063 Blon_2468 Proteins 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 101700007082 EBAG Proteins 0.000 claims 1
- 101710035898 ENGASE Proteins 0.000 claims 1
- 102100011011 ENGASE Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 239000002075 main ingredient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
Claims (33)
Ga1 (6S)-G1cNAc (6S),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир.5. The anti-inflammatory agent according to any one of claims 2 to 4, wherein said keratan sulfate oligosaccharide contains at least a disaccharide of the formula as a constituent ingredient
Ga1 (6S) -G1cNAc (6S),
where Ga1 represents galactose;
G1cN is glucosamine;
Ac represents an acetyl group;
6S is 6-O-sulfate ester.
Ga1(6S)β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (I)
NeuAc~Ga1β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (II)
Ga1(6S)β1-4G1cNAc(6S) (III),
где Gal представляет галактозу;
G1cN представляет глюкозамин;
Neu представляет нейраминовую кислоту;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир;
~ обозначает связь α2,3 или связь α2,6.6. The anti-inflammatory agent according to claim 5, wherein said keratan sulfate oligosaccharide is selected from the group consisting of tetrasulfated N-acetylactosaminotetrasaccharide represented by formula I, trisulfated N-acetyl lactosaminopentasaccharide represented by formula II, disulfated N-acetyl lactosulodisamine:
Ga1 (6S) β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (I)
NeuAc ~ Ga1β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (II)
Ga1 (6S) β1-4G1cNAc (6S) (III),
where Gal represents galactose;
G1cN is glucosamine;
Neu is neuraminic acid;
Ac represents an acetyl group;
6S is 6-O-sulfate ester;
~ denotes a bond α2,3 or a bond α2,6.
Ga1 (6S)-G1cNAc (6S),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир.10. The antiallergic agent according to any one of claims 7 to 9, wherein said keratan sulfate oligosaccharide contains at least a disaccharide of the formula as a constituent ingredient
Ga1 (6S) -G1cNAc (6S),
where Ga1 represents galactose;
G1cN is glucosamine;
Ac represents an acetyl group;
6S is 6-O-sulfate ester.
Ga1(6S)β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (I)
NeuAc~Ga1β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAcNAc(6S) (II)
Ga1(6S)β1-4G1cNAc(6S) (III),
где Ga1 представляет гадактозу;
G1cN представляет глюкозамин;
Neu представляет нейраминовую кислоту;
Ас представляет ацетильную грцппу;
6S представляет 6-О-сульфатный эфир;
~ обозначает связь α 2,3 или связь α 2,6.11. The antiallergic agent of claim 10, wherein said keratan sulfate oligosaccharide is selected from the group consisting of tetrasulfated N-acetylactosaminotetrasaccharide represented by Formula I, trisulfated N-acetyl lactosaminopentasaccharide represented by Formula II, and disulfated N-acetyl sulactosamine:
Ga1 (6S) β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (I)
NeuAc ~ Ga1β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAcNAc (6S) (II)
Ga1 (6S) β1-4G1cNAc (6S) (III),
where Ga1 is gadactose;
G1cN is glucosamine;
Neu is neuraminic acid;
Ac is an acetyl group;
6S is 6-O-sulfate ester;
~ denotes a bond α 2,3 or a bond α 2,6.
Ga1 (6S)-G1cNAc(6S),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир.15. The immunomodulator according to any one of claims 12-14, wherein said keratan sulfate oligosaccharide contains at least a disaccharide of the formula as a constituent ingredient
Ga1 (6S) -G1cNAc (6S),
where Ga1 represents galactose;
G1cN is glucosamine;
Ac represents an acetyl group;
6S is 6-O-sulfate ester.
Ga1(6S)β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (I)
NeuAc~Ga1β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (II)
Ga1(6S)β1-4G1cNAc(6S) (III),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Neu представляет нейраминовую кислоту;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир;
~ обозначает связь α2,3 или связь α2,6.16. The immunomodulator according to clause 15, wherein said keratan sulfate oligosaccharide is selected from the group consisting of tetrasulfated N-acetylactosaminotetrasaccharide represented by Formula I, trisulfated N-acetyl lactosaminopentasaccharide represented by Formula II, and disulfated N-acetyl lactosodisamine:
Ga1 (6S) β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (I)
NeuAc ~ Ga1β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (II)
Ga1 (6S) β1-4G1cNAc (6S) (III),
where Ga1 represents galactose;
G1cN is glucosamine;
Neu is neuraminic acid;
Ac represents an acetyl group;
6S is 6-O-sulfate ester;
~ denotes a bond α2,3 or a bond α2,6.
Ga1 (6S)-G1cNAc (6S),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир.20. The inducer of cell differentiation according to any one of paragraphs.17-19, where the specified keratan sulfate oligosaccharide contains as a component ingredient at least a disaccharide of the formula
Ga1 (6S) -G1cNAc (6S),
where Ga1 represents galactose;
G1cN is glucosamine;
Ac represents an acetyl group;
6S is 6-O-sulfate ester.
Ga1(6S)β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (I)
NeuAc~Ga1β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (II)
Ga1(6S)β1-4G1cNAc(6S) (III),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Neu представляет нейраминовую кислоту;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир;
~ обозначает связь α2,3 или связь α2,6.21. The cell differentiation inducer of claim 20, wherein said keratan sulfate oligosaccharide is selected from the group consisting of tetrasulfated N-acetylactosaminotetrasaccharide represented by formula I, trisulfated N-acetyl lactosaminopentasaccharide represented by formula II, and disulfated N-acetyl saccharide:
Ga1 (6S) β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (I)
NeuAc ~ Ga1β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (II)
Ga1 (6S) β1-4G1cNAc (6S) (III),
where Ga1 represents galactose;
G1cN is glucosamine;
Neu is neuraminic acid;
Ac represents an acetyl group;
6S is 6-O-sulfate ester;
~ denotes a bond α2,3 or a bond α2,6.
Ga1 (6S)-G1cNAc (6S),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир.25. The apoptosis inducer according to any one of claims 22-24, wherein said keratan sulfate oligosaccharide contains at least a disaccharide of the formula as a constituent ingredient
Ga1 (6S) -G1cNAc (6S),
where Ga1 represents galactose;
G1cN is glucosamine;
Ac represents an acetyl group;
6S is 6-O-sulfate ester.
Ga1(6S)β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (I)
NeuAc~Ga1β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (II)
Ga1(6S)β1-4G1cNAc(6S) (III),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Neu представляет нейраминовую кислоту;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир;
~ обозначает связь α2,3 или связь α2,6.26. The apoptosis inducer of claim 25, wherein said keratan sulfate oligosaccharide is selected from the group consisting of tetrasulfated N-acetylactosaminotetrasaccharide represented by Formula I, trisulfated N-acetyl lactosaminopentasaccharide represented by Formula II, and disulfated N-acetyl saccharide:
Ga1 (6S) β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (I)
NeuAc ~ Ga1β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (II)
Ga1 (6S) β1-4G1cNAc (6S) (III),
where Ga1 represents galactose;
G1cN is glucosamine;
Neu is neuraminic acid;
Ac represents an acetyl group;
6S is 6-O-sulfate ester;
~ denotes a bond α2,3 or a bond α2,6.
Ga1 (6S)-G1cNAc (6S),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир.28. The keratan sulfate oligosaccharide fraction according to claim 27, wherein said keratan sulfate oligosaccharide contains at least a disaccharide of the formula
Ga1 (6S) -G1cNAc (6S),
where Ga1 represents galactose;
G1cN is glucosamine;
Ac represents an acetyl group;
6S is 6-O-sulfate ester.
Ga1(6S)β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (I)
NeuAc-Ga1β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (II)
Ga1(6S)β1-4G1cNAc(6S) (III),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Neu представляет нейраминовую кислоту;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир;
~ обозначает связь α2,3 или связь α2,6.29. The keratan sulfate oligosaccharide fraction according to claim 27 or 28, wherein said keratan sulfate oligosaccharide is selected from the group consisting of tetrasulfated N-acetylactosaminotetrasaccharide represented by Formula I, trisulfated N-acetyl lactosaminopentasaccharide represented by Formula II, Formula II and
Ga1 (6S) β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (I)
NeuAc-Ga1β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (II)
Ga1 (6S) β1-4G1cNAc (6S) (III),
where Ga1 represents galactose;
G1cN is glucosamine;
Neu is neuraminic acid;
Ac represents an acetyl group;
6S is 6-O-sulfate ester;
~ denotes a bond α2,3 or a bond α2,6.
(1) оптимальный рН реакции: расщепляющий фермент имеет оптимальный рН реакции 4,5 - 6 в 0,1М ацетатном буфере или в 10 мМ трис-ацетатном буфере при 37oC;
(2) рН стабильность: расщепляющий фермент обладает рН стабильностью 6 - 7, когда расщепляющий фермент остается в 0,1М ацетатном буфере или в 10 мМ трис-ацетатном буфере при 37oC в течение 1 ч;
(3) оптимальная температура реакции: расщепляющий фермент имеет оптимальную температуру реакции 50 - 60oC, когда расщепляющий фермент реагирует в 0,1М ацетатном буфере, рН 6,0, в течение 10 мин; и
(4) термоустойчивость: расщепляющий фермент устойчив, по меньшей мере, при 45oC или ниже, когда расщепляющий фермент остается в 0,1М ацетатном буфере, рН 6,0, в течение 1 ч.32. The method for producing the keratan sulfate oligosaccharide fraction according to Claim 31, wherein, in the cleavage step with said keratan sulfate cleaving enzyme, the keratan sulfate cleaving enzyme, in addition to the properties described in clause 31, has the following physical and chemical properties:
(1) optimal reaction pH: the cleavage enzyme has an optimal reaction pH of 4.5-6 in 0.1 M acetate buffer or in 10 mM Tris acetate buffer at 37 ° C;
(2) pH stability: the cleavage enzyme has a pH stability of 6-7 when the cleavage enzyme remains in 0.1 M acetate buffer or in 10 mM Tris acetate buffer at 37 ° C. for 1 hour;
(3) the optimum reaction temperature: the cleavage enzyme has an optimum reaction temperature of 50-60 ° C when the cleavage enzyme is reacted in 0.1 M acetate buffer, pH 6.0, for 10 minutes; and
(4) thermal stability: the degrading enzyme is stable at least at 45 ° C. or lower when the degrading enzyme remains in 0.1 M acetate buffer, pH 6.0, for 1 hour.
Ga1(6S)β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (I)
NeuAc-Ga1β1-4G1cNAc(6S)β1-3Ga1(6S)β1-4G1cNAc(6S) (II)
Ga1(6S)β1-4G1cNAc(6S) (III),
где Ga1 представляет галактозу;
G1cN представляет глюкозамин;
Neu представляет нейраминовую кислоту;
Ас представляет ацетильную группу;
6S представляет 6-О-сульфатный эфир;
~ обозначает связь α2,3 или связь α2,6.33. The method of producing the keratan sulfate oligosaccharide fraction according to claim 31 or 32, wherein said keratan sulfate is a highly sulfated keratan sulfate and the keratan sulfate oligosaccharide is selected from the group consisting of tetrasulfated N-acetyl lactosaminotetrasaccharides-disulfonated sulphonated sulphonated represented by formula III:
Ga1 (6S) β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (I)
NeuAc-Ga1β1-4G1cNAc (6S) β1-3Ga1 (6S) β1-4G1cNAc (6S) (II)
Ga1 (6S) β1-4G1cNAc (6S) (III),
where Ga1 represents galactose;
G1cN is glucosamine;
Neu is neuraminic acid;
Ac represents an acetyl group;
6S is 6-O-sulfate ester;
~ denotes a bond α2,3 or a bond α2,6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/298298 | 1994-12-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97111163A true RU97111163A (en) | 1999-06-10 |
RU2173154C2 RU2173154C2 (en) | 2001-09-10 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meyer | 11 Hyaluronidases | |
Ernst et al. | Enzymatic degradation of glycosaminogIycans | |
Jansson et al. | Structure of the extracellular polysaccharide from Xanthomonas campestris | |
Karst et al. | Recent chemical and enzymatic approaches to the synthesis of glycosaminoglycan oligosaccharides | |
Shi et al. | Chondroitin sulfate: Extraction, purification, microbial and chemical synthesis | |
EP2123663B1 (en) | Method for production of sugar oxazoline derivative | |
Helting et al. | Occurrence and biosynthesis of β-glucuronidic linkages in heparin | |
HU214986B (en) | Process for producing preparation containing n,o-sulfated heparosanes | |
Safaiyan et al. | Selective reduction of 6‐O‐sulfation in heparan sulfate from transformed mammary epithelial cells | |
Silbert | Structure and metabolism of proteoglycans and glycosaminoglycans | |
Pejler et al. | Basement-membrane heparan sulphate with high affinity for antithrombin synthesized by normal and transformed mouse mammary epithelial cells | |
US6545136B1 (en) | Process for producing desulfated polysaccharide, and desulfated heparin | |
Rapport et al. | The hydrolysis of hyaluronic acid by pneumococcal hyaluronidase | |
Molist et al. | Changes in glycosaminoglycan structure and composition of the main heparan sulphate proteoglycan from human colon carcinoma cells (perlecan) during cell differentiation | |
Kubo et al. | Depolymerization of hyaluronan by sonication | |
Sutherland et al. | The exopolysaccharide of Klebsiella aerogenes A 3 (Sl)(type 54). The isolation of O-acetylated octasaccharide, tetrasaccharide and trisaccharide | |
Endo et al. | Synthesis of neoproteoglycans using the transglycosylation reaction as a reverse reaction of endo-glycosidases | |
RU97111163A (en) | FACTION OF KERATAN SULPHATOLIGOSACCHARIDES AND ITS PHARMACEUTICAL PRODUCT | |
Linker et al. | The enzymatic degradation of heparitin sulfate: II. Isolation and characterization of non-sulfated oligosaccharides | |
JP3650409B2 (en) | Process for producing low molecular weight branched β-1,3-glucan and branched laminary oligosaccharide | |
Garg et al. | Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecular-weight heparin derivative | |
Tamura | Recent aspects of proteoglycan syntheses | |
JP3522775B2 (en) | Heparin unsaturated tetrasaccharide and method for producing the same | |
JPH09263595A (en) | Production of sulfated lactosamine oligosaccharide | |
Linker | The uronidic linkages in heparitin sulfate |